EDAP TMS SA (FOCL): Results of Operations and Financial Condition
EDAP TMS SA (FOCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026 AUSTIN, Texas, August 11, 2026 - FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced preliminary unaudited financial results for the Com
How this was made
The 30-second read
Why it matters
The most tradable elements are the quantified preliminary commercial KPIs (HIFU revenue range, system sales growth, installed base growth, procedure volume growth) and the cash balance, alongside the operating loss range.
Market read
FOCL provides a fresh snapshot of Q2’26 commercialization momentum and liquidity, which can drive near-term sentiment and positioning ahead of more complete audited reporting.
What to watch
The filing highlights a shift of certain legacy ESWL and distribution financials to discontinued operations effective Q2’26, which can complicate comparisons versus prior periods and affect how investors normalize profitability.
Preliminary Q2’26 HIFU Revenue of $12.7M – $13.2M, with +34% - +39% YoY Growth
Preliminary HIFU revenue, capital-system sales, installed base, procedure volume and HIFU gross margin all showed reported year-over-year growth, while the company continued to report an operating loss.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| HIFU Revenueother | $12.7M – $13.2M | – | +34% - +39% YoY Growth |
| HIFU Capital Salesother | 13 Focal One System Sales | – | +44% YoY Growth |
| Global HIFU Installed Baseother | 184 Focal One Systems | – | +38 vs. 146 in Q2'25 |
| Focal One U.S. Procedure Volumeother | +47% YoY Growth | – | +47% YoY Growth |
| HIFU Gross Marginother | 54% – 56% | – | +3% - +5% YoY Growth |
| Operating Profit / (Loss)other | ($8.5M) – ($7.5M) | – | – |
| Cashother | $21.5M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| HIFURecord second quarter HIFU Revenue; four additional health systems purchased a second or subsequent system during the quarter, and the company cited installations at Imperial College Healthcare NHS Trust London, Nice University Hospital, and leading centers in India. | $12.7M – $13.2M | – | +34% - +39% YoY Growth |
What drove it
- Strong commercial execution with record second quarter HIFU Revenue.
- Four additional health systems purchased a second or subsequent system during the quarter.
- New installations at Imperial College Healthcare NHS Trust London, Nice University Hospital, and leading centers in India.
- The company launched its first commercial endometriosis program at Toulouse University Hospital.
- The company cited parallel on-going international BPH studies and an approved IRB in the U.S.
- The company continued development of proprietary Focal One-based histotripsy technology.
Concerns
- Financial results are preliminary and unaudited.
- Operating Profit / (Loss) was reported as ($8.5M) – ($7.5M).
- The company shifted reporting of legacy non-core ESWL and distribution financials to discontinued operations effective Q2'26.
- Focal One for BPH and deep infiltrating endometriosis is described as not available for sale in the U.S.
What to watch
- Conversion of the 184 Focal One Systems installed base into continued U.S. procedure-volume growth.
- Additional repeat purchases by hospital networks and international installations.
- Commercial progress from the Toulouse University Hospital endometriosis program.
- Progress of international BPH studies and the approved U.S. IRB.
- Development of proprietary Focal One-based histotripsy technology.
- The proposed +11.6% 2027 OPPS HIFU reimbursement change cited by the company.
Balance sheet and cash flow
- Cash $21.5M
- In April 2026, the Company drew €12.0M in Tranche B borrowings from its EIB credit facility.
Analysis
The preliminary Q2'26 release centers on accelerating HIFU commercial activity. HIFU Revenue was reported at $12.7M – $13.2M, representing +34% - +39% YoY Growth, while HIFU Capital Sales totaled 13 Focal One System Sales, up +44% YoY Growth. The company characterized the period as a record second quarter for HIFU Revenue and cited four additional health systems purchasing a second or subsequent system during the quarter.
The installed base and procedure metrics support the commercial narrative. Global HIFU Installed Base reached 184 Focal One Systems, compared with 146 in Q2'25, and Focal One U.S. Procedure Volume showed +47% YoY Growth. The release also identified installations at Imperial College Healthcare NHS Trust London, Nice University Hospital, and leading centers in India, extending the reported commercial activity beyond the U.S.
Mix and profitability data are limited to HIFU. HIFU Gross Margin was 54% – 56%, with +3% - +5% YoY Growth, but Operating Profit / (Loss) remained ($8.5M) – ($7.5M). The company also shifted legacy non-core ESWL and distribution financials to discontinued operations effective Q2'26, making the HIFU-focused reporting presentation a significant change from prior reporting periods.
Liquidity disclosure consisted of Cash of $21.5M and a €12.0M draw in April 2026 under Tranche B of the EIB credit facility. There were no reported operating or free-cash-flow figures, debt balance, capital-return activity, or formal company financial guidance in the provided filing text. The financial figures are explicitly described as preliminary and unaudited.
Strategically, the company highlighted a first commercial endometriosis program at Toulouse University Hospital, parallel international BPH studies with an approved U.S. IRB, and continued development of Focal One-based histotripsy technology. The release also cited proposed +11.6% 2027 OPPS reimbursement for HIFU for prostate cancer. The principal figures to monitor are the conversion of installed systems into procedures, repeat health-system purchases, HIFU gross margin, and the operating-loss range.
Not in the filing
stated, not guessed- Period end date.
- Total revenue.
- Revenue from ESWL, distribution, or any other segment.
- GAAP gross margin, operating income, net income, and EPS.
- Non-GAAP gross margin, operating income, net income, and EPS.
- Prior-quarter comparisons for reported HIFU metrics.
- Absolute prior-year HIFU revenue, capital-sales, procedure-volume, and gross-margin figures.
- Operating cash flow.
- Free cash flow.
- Total debt balance and debt maturity information.
- Share repurchases, dividends, or other capital-return activity.
- Formal forward financial guidance for revenue, gross margin, operating expenses, tax rate, or earnings.
- Previous-quarter outlook for comparison with actual results.
- Named executive quotes.
- Cash-flow and balance-sheet comparison periods.
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
The 8-K (Item 2.02) includes Exhibit 99.2 with preliminary Q2’26 financial results and business updates for EDAP TMS SA, now rebranded to FocalTherics (NASDAQ: FOCL).
Ticker impact
EDAP TMS SA (rebranded to FocalTherics) filed an 8-K with preliminary Q2’26 results, including HIFU revenue, system sales, and cash balance.
Moderate upside bias if investors view the record HIFU revenue and rising installed base as validating adoption momentum; downside risk if operating loss and cash burn concerns dominate.
The filing provides multiple quantified commercial KPIs (revenue range, system sales growth, installed base, procedure volume) plus cash on hand, but it is preliminary and unaudited, and the operating loss range is still sizable.
Market effects
Reinforces demand signals for therapeutic ultrasound and focal therapy platforms, which can influence sentiment toward small-cap medtech peers with similar commercialization narratives.
Limited direct regional read-through; international installation mentions may support broader investor confidence in non-US adoption.
Primarily company-specific, but international hospital network expansion can be a positive read-through for global procedure equipment adoption.
Counterpoint
Preliminary, unaudited results with an operating loss range may mean the market is over-weighting top-line growth while underestimating margin pressure and cash burn.
Key entities
- issuerEDAP TMS SA
Company filing the 8-K with preliminary Q2’26 results and business updates for its Focal One therapeutic ultrasound platform.
- brandFocalTherics
Rebranded name referenced in the filing, associated with the NASDAQ listing FOCL.
- financingEIB credit facility
Company drew €12.0M in Tranche B borrowings in April 2026, supporting the cash position referenced in the filing.
